This strategy, explored by Hunt et al., involves using antagomirs or target-site blockers to inhibit miRNAs that suppress AAT expression, potentially enhancing the antiprotease shield in CF lungs [88]. The gene discussed is SERPINA1; the disease is cystic fibrosis.